Oct 2026· European Heart Journal· Vol 47· 0 citations
TL;DR
Relatives with gene-elusive HCM identified through family screening exhibit a predominantly mild structural phenotype, lower arrhythmic burden, and few adverse outcomes compared with probands, which suggests a significant contribution to disease expression in this subgroup.
Abstract
Hypertrophic cardiomyopathy (HCM) has traditionally been viewed as a monogenic disorder. Increasing evidence indicates that gene-elusive HCM represents a distinct subgroup with differing clinical characteristics. Understanding its familial expression and natural history is essential to inform personalised management strategies.
To characterise the phenotype and clinical outcomes of affected relatives in gene-elusive HCM and compare them with probands.
Among 842 patients referred for HCM genetic testing over a 10-year period, 637 with clinical follow-up were enrolled in a natural history registry. Families in which probands had negative genetic testing (HCMG–) were included. Of 1,278 at-risk relatives, 74 (9.7%) were diagnosed with HCM through screening; 28 had complete follow-up. These were compared with 294 probands.
Affected relatives were younger at diagnosis than probands (48.4 ± 16.1 vs 54.1 ± 12.6 years; p = 0.032), with similar follow-up (6.6 ± 5.1 vs 6.4 ± 3.8 years; p = 0.88). Relatives demonstrated a milder structural phenotype: isolated basal septal hypertrophy was more common (42.3% vs 5.1%) and apical hypertrophy less frequent (11.5% vs 31.0%; p < 0.001). Maximal wall thickness (14.0 ± 2.4 vs 16.6 ± 3.3 mm; p < 0.001) and left atrial diameter (38.1 ± 4.8 vs 41.9 ± 6.1 mm; p = 0.003) were lower. Seventy-five percent had borderline wall thickness (13–15 mm).
Cardiovascular risk factors were highly prevalent: 50% of relatives were hypertensive at diagnosis, and 93% had ≥1 risk factor by final follow-up.
Relatives were less symptomatic (46.4% vs 78.2%; p < 0.001), had fewer patients in NYHA class ≥ II, and showed a lower prevalence of LV outflow tract obstruction (3.7% vs 26.2%; p = 0.03). Arrhythmias were less common: atrial fibrillation/flutter occurred in 15.4% of relatives vs 29.5% of probands. Only three cardiovascular events occurred in relatives (fast atrial fibrillation, stroke, acute pericarditis). Sudden cardiac death (SCD) risk was low in both groups but lowest in relatives: only one had an estimated SCD risk ≥4%, compared with 9.8% of probands. All symptomatic ventricular arrhythmias occurred in probands.
Relatives with gene-elusive HCM identified through family screening exhibit a predominantly mild structural phenotype, lower arrhythmic burden, and few adverse outcomes compared with probands. The high prevalence of cardiovascular risk factors among relatives suggests a significant contribution to disease expression in this subgroup.Affected Relatives vs ProbandsCV Risk at Diagnosis: Affected Relatives
Hypertrophic cardiomyopathy (HCM) has traditionally been viewed as a monogenic disease. Increasing evidence, however, suggests that gene-elusive HCM constitutes a distinct subgroup. A clearer understanding of its natural history is essential to support tailored management strategies.
To characterise clinic...
P. M. Marin, K. Halim, P. Poveda et al.· European Heart Journal· 0 citations
Screening yield is driven by uptake levels and existing family history, supporting systematic phenotypic screening even when no causative genetic variant is detected, and clinical cascade screening identifies new diagnoses in a modest but clinically meaningful proportion of relatives.
P. M. Marin, D. Tardo, K. Halim et al.· European Heart Journal· 0 citations
BACKGROUND
Family screening is recommended in dilated cardiomyopathy (DCM), but risk stratification of relatives of probands without pathogenic or likely pathogenic variants (gene-elusive) remains uncertain.
OBJECTIVES
This study sought to define the incidence, prognosis, and predictors of disease development in firs...
A. Paldino, E. Del Mestre, I. Gandin et al.· JACC. Heart failure· 0 citations
BACKGROUND
Dilated cardiomyopathy (DCM) frequently presents with heart failure in children. Whether a genetic cause of DCM is associated with disease severity or eventual outcome in pediatric DCM is unclear.
METHODS
A multiinstitutional prospective pediatric cohort study (0-18 years) with nonsyndromic DCM was underta...
Paul F. Kantor, Stephanie M. Ware, Wendy K. Chung et al.· Circulation: Heart Failure· 0 citations
Bicuspid aortic valve (BAV) affects 0.8% of the population and demonstrates high heritability with up to 89% of the variation in the trait being determined by genetic factors, yet the clinical utility of familial screening and genetic testing in unselected cohorts remains poorly defined/examined. Current European...
J. Bruhn, J. Norsk, A. Sillesen et al.· European Heart Journal· 0 citations
Dilated cardiomyopathy (DCM) is a common heritable cardiomyopathy with substantial clinical and genetic heterogeneity (≈1 in 200). Determining whether a patient carries a likely pathogenic/pathogenic (LP/P) variant is clinically important since genotype status is associated with differences in disease course and...
F. El Kayouhi, L. Arts, F. Raijmakers et al.· European Heart Journal· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.